Immunotherapies for cancer and infectious diseases
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancer and infectious diseases.
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancer and infectious diseases.
Latest News
- July 31, 2017 - First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
- July 24, 2017 - Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
- June 29, 2017 - Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
- June 22, 2017 - Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
